Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
Rhea-AI Summary
Microbot Medical (Nasdaq: MBOT) announced Emory University Hospital as the first hospital to adopt the LIBERTY Endovascular Robotic System for patient care, and a collaboration to establish an Endovascular Robotics Program in interventional radiology.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The company commenced a limited market release and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Positive
- FDA-cleared single-use endovascular robotic system
- Emory University Hospital named first adopter
- Company began a limited market release
- Full market release planned for April 2026 at SIR
Negative
- Product availability in limited market release until full April 2026 rollout
News Market Reaction
On the day this news was published, MBOT gained 21.81%, reflecting a significant positive market reaction. Argus tracked a peak move of +19.6% during that session. Our momentum scanner triggered 52 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $28M to the company's valuation, bringing the market cap to $157M at that time. Trading volume was exceptionally heavy at 6.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MBOT was down 2.44% pre-news while peers were mixed: AVR -2.05%, KRMD -1.01%, INFU +0.33%, STXS +2.98%, NYXH -1.81%, suggesting stock-specific dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | First hospital adoption | Positive | +21.8% | Emory University Hospital became first clinical adopter of LIBERTY system. |
| Nov 05 | Limited market release | Positive | +5.0% | LIBERTY system entered limited U.S. commercial release targeting key regions. |
| Oct 16 | Conference debut | Positive | -2.7% | Planned commercial debut of LIBERTY at interventional oncology meeting. |
| Oct 14 | Logistics partnership | Positive | -4.3% | Signed U.S. logistics partner to support LIBERTY commercialization and launch. |
| Oct 07 | Capital raise/options | Neutral | +0.3% | Completed preferred option exercises raising cash and issuing new Series J options. |
Recent LIBERTY commercialization milestones tended to produce strong upside when tied to concrete adoption or market release, while preparatory or logistical updates showed mixed or negative price alignment.
This announcement extends a string of LIBERTY-related commercialization milestones. After FDA 510(k) clearance in early September 2025, MBOT highlighted commercial debut plans in October and secured a U.S. logistics partner for distribution. On Nov 5, 2025, it began a limited U.S. market release, followed by this first clinical adoption at Emory on Nov 26, 2025, which previously saw a 21.81% gain. Separately, MBOT raised about $29.2M via preferred investment option exercises, with additional potential proceeds through Series J options.
Regulatory & Risk Context
MBOT has an active Form S-3/A shelf amendment filed on 2025-10-28, primarily adding Rule 473(b) language for automatic effectiveness. Disclosed offering-related expenses total $25,000.00, and the shelf has been used in connection with two Rule 424(b)(3) resale prospectuses filed on 2025-11-19.
Market Pulse Summary
The stock surged +21.8% in the session following this news. A strong positive reaction aligns with how MBOT previously traded on LIBERTY adoption news, as the prior Emory announcement coincided with a 21.81% move. Investors have seen a sequence from FDA 510(k) clearance to limited market release and now first-hospital adoption. However, recent capital raises and resale registrations, plus an effective shelf framework, could introduce overhang if additional equity usage followed, so sustainability historically depended on ongoing execution milestones.
Key Terms
endovascular medical
interventional radiology medical
embolization medical
robotic system technical
AI-generated analysis. Not financial advice.
Adoption of LIBERTY is Consistent with Emory’s Commitment to the Growing and Evolving Field of Interventional Radiology
HINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University Hospital, a nationally recognized academic medical center in Atlanta, has become the first hospital to adopt LIBERTY for patient care. Additionally, Microbot is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology to enhance the growing and evolving specialty field.
LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. Just weeks ago, the Company commenced the limited market release of the system and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.
Emory University Hospital is a leading academic medical center recognized for its excellence in patient care, research, and innovation. With the hospital’s strengths in endovascular and oncology services, Microbot will support clinicians in delivering precise care for peripheral intervention procedures such as liver tumor embolization, prostate artery embolization and uterine fibroid embolization, among others.
“Introducing innovative technologies such as LIBERTY to our interventional radiology program underscores our priority to remain at the forefront of technological advancement. We anticipate that its single-use, remotely operated design will offer a practical and scalable approach to robotics that supports our operational goals, protects our clinicians and provides access to quality care,” says J. David Prologo, MD, division director for Interventional Radiology, Emory University School of Medicine.
“This is an extraordinary occasion for Microbot Medical, and we believe a major milestone for the entire surgical robotic space. We are establishing a completely new medical robotic category with the adoption of the first FDA-cleared single-use robotic system. This achievement reflects years of dedication and sustained progress by the entire team,” commented Harel Gadot, CEO, President & Chairman. “Emory University Hospital clinicians and researchers have demonstrated enthusiasm early on about this technology and in providing additional access to new technology for physicians and patients in the evolving field of medical robotics. We are proud to welcome them as the first adopter of LIBERTY, and we are committed to supporting them every step of the way to ensure clinical and operational success.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Commercialization Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation
Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ
What does Emory adopting LIBERTY mean for Microbot Medical (MBOT)?
Is LIBERTY FDA cleared and what makes it unique for MBOT (MBOT)?
When will Microbot Medical (MBOT) conduct its full LIBERTY market release?
What clinical procedures will LIBERTY support at Emory Hospital?
Has Microbot Medical (MBOT) already started commercial use of LIBERTY?
How does LIBERTY aim to affect clinicians using the system at Emory (MBOT)?
